Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ZITHROMAX.
E.E.S. 200 vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic